Honored that Didier Betbeder, our CSO, was invited to present the Vaxinano mucosal vaccine platform at the Conference: Harnessing airway immunity for next-gen vaccines, organized by the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Nordisk Foundation Science Cluster in Copenhagen.
Over 3 inspiring and insightful days, we had the opportunity to present our Vaxinano mucosal vaccine platform — an innovative technology designed to strengthen local immunity, block transmission, and address critical challenges in respiratory infectious diseases.
The event clearly highlighted that the future of vaccines lies in approaches capable of directly targeting the airways, going beyond systemic protection. We are proud that Vaxinano is contributing to this shift with cuttind-edge science and trasnlational innovation.
Many thanks to the organizers for creating such a dynamic forum for collaboration between researchers, clinicians, biotechs, vaccine developers, and regulators.
With Vaxinano, we remain fully committed to advancing next-generation vaccines for a healthier future.
#Vaccines hashtag#MucosalImmunity hashtag#Innovation hashtag#Vaxinano